$296 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 79 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RLMD | New | RELMADA THERAPEUTICS INCput | $14,549,000 | – | 393,000 | +100.0% | 4.92% | – |
| PRTA | New | PROTHENA CORP PLC | $6,669,000 | – | 110,000 | +100.0% | 2.26% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $6,514,000 | – | 32,545 | +100.0% | 2.20% | – |
| CLNN | New | CLENE INCput | $4,857,000 | – | 1,734,800 | +100.0% | 1.64% | – |
| PLRX | New | PLIANT THERAPEUTICS INC | $4,383,000 | – | 209,822 | +100.0% | 1.48% | – |
| ABOS | New | ACUMEN PHARMACEUTICALS INC | $4,213,000 | – | 420,000 | +100.0% | 1.42% | – |
| ISEE | New | IVERIC BIO INC | $3,182,000 | – | 177,364 | +100.0% | 1.08% | – |
| LVTX | New | LAVA THERAPEUTICS NV | $2,791,000 | – | 610,809 | +100.0% | 0.94% | – |
| ALLK | New | ALLAKOS INC | $2,448,000 | – | 400,000 | +100.0% | 0.83% | – |
| KRTX | New | KARUNA THERAPEUTICS INC | $2,322,000 | – | 10,323 | +100.0% | 0.78% | – |
| PNT | New | POINT BIOPHARMA GLOBAL INC | $2,319,000 | – | 300,000 | +100.0% | 0.78% | – |
| ESPR | New | ESPERION THERAPEUTICS INC NE | $2,104,000 | – | 314,095 | +100.0% | 0.71% | – |
| ARVN | New | ARVINAS INC | $1,813,000 | – | 40,741 | +100.0% | 0.61% | – |
| NTLA | New | INTELLIA THERAPEUTICS INC | $1,791,000 | – | 32,011 | +100.0% | 0.61% | – |
| IMVT | New | IMMUNOVANT INC | $1,674,000 | – | 300,000 | +100.0% | 0.57% | – |
| BCAB | New | BIOATLA INC | $1,543,000 | – | 200,422 | +100.0% | 0.52% | – |
| ETNB | New | 89BIO INC | $1,448,000 | – | 250,000 | +100.0% | 0.49% | – |
| TRVI | New | TREVI THERAPEUTICS INC | $1,446,000 | – | 939,265 | +100.0% | 0.49% | – |
| ALT | New | ALTIMMUNE INC | $1,283,000 | – | 100,469 | +100.0% | 0.43% | – |
| AVXL | New | ANAVEX LIFE SCIENCES CORPcall | $1,032,000 | – | 100,000 | +100.0% | 0.35% | – |
| New | NUVALENT INC | $806,000 | – | 41,439 | +100.0% | 0.27% | – | |
| CMPX | New | COMPASS THERAPEUTICS INC | $598,000 | – | 262,090 | +100.0% | 0.20% | – |
| ASND | New | ASCENDIS PHARMA A/Ssponsored adr | $516,000 | – | 5,000 | +100.0% | 0.18% | – |
| MGNX | New | MACROGENICS INC | $346,000 | – | 100,000 | +100.0% | 0.12% | – |
| PRTA | New | PROTHENA CORP PLCput | $303,000 | – | 5,000 | +100.0% | 0.10% | – |
| NCNA | New | NUCANA PLCsponsored adr | $282,000 | – | 269,682 | +100.0% | 0.10% | – |
| PRAX | New | PRAXIS PRECISION MEDICINES I | $227,000 | – | 100,000 | +100.0% | 0.08% | – |
| TERN | New | TERNS PHARMACEUTICALS INC | $85,000 | – | 14,473 | +100.0% | 0.03% | – |
| PYPD | New | POLYPID LTDput | $59,000 | – | 50,000 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-10-28
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| 13F-HR | 2022-10-28 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.